Cocrystal Pharma, Inc.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

COCP$1.11+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

	June 30, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash	$4,766	$9,860
Restricted cash	75	75
Tax credit receivable	1,642	1,215
Prepaid expenses and other current assets	282	430
Total current assets	6,765	11,580
Property and equipment, net	107	153
Deposits	88	29
Operating lease right-of-use assets, net (including $127 and $152 to related party)	1,545	1,694
Total assets	$8,505	$13,456
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$1,514	$2,127
Current maturities of operating lease liabilities (including $52 and $49 to related party)	317	301
Total current liabilities	1,831	2,428
Long-term liabilities:
Operating lease liabilities (including $77 and $104 to related party)	1,341	1,505
Total long-term liabilities	1,341	1,505
Total liabilities	3,172	3,933
Commitments and contingencies	-	-
Stockholders’ equity:
Common stock, $0.001 a par value: 100,000 shares authorized as of June 30, 2025, and December 31, 2024; 10,174 shares issued and outstanding as of June 30, 2025 and December 31, 2024	10	10
Additional paid-in capital	343,097	342,931
Accumulated deficit	(337,774)	(333,418)
Total stockholders’ equity	5,333	9,523
Total liabilities and stockholders’ equity	$8,505	$13,456

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.